Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00069
|
|||||
| Drug Name |
Cabergoline
|
|||||
| Synonyms |
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea; CG-101; Cabaser; Cabaser (TN); Cabaseril; Cabergolina; Cabergolina [Spanish]; Cabergoline (JAN/USAN/INN); Cabergoline [USAN:BAN:INN]; Cabergolinum; Cabergolinum [Latin]; Dostinex; Dostinex (TN); FCE-21336; Galastop; Sogilen
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hyperprolactinemia [ICD11:5A60.1] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H37N5O2
|
|||||
| Canonical SMILES |
CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
|
|||||
| InChI |
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
|
|||||
| InChIKey |
KORNTPPJEAJQIU-KJXAQDMKSA-N
|
|||||
| CAS Number |
CAS 81409-90-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 451.6 | Topological Polar Surface Area | 71.7 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
3.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103771070
,10387
,104305757
,117539013
,118047283
,12013713
,126624984
,126656189
,126684133
,134337565
,135013805
,135652674
,135989394
,137001464
,142175117
,144206142
,14759961
,14808642
,152101006
,160963596
,162179026
,163133315
,164155372
,164824353
,170464667
,175267048
,176484246
,179151225
,184546096
,196111573
,223682255
,223820795
,226427091
,252222293
,252391240
,34718715
,46508571
,48415679
,49965419
,53787199
,57313654
,75968790
,7848050
,7978840
,8183775
,85788035
,92309005
,92713133
,92740959
,93166933
|
|||||
| ChEBI ID |
CHEBI:3286
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Cabergoline was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.